Advancing a Circular RNA Vaccine
Platform for the Next Generation of
Infectious Disease Prevention

Vaxxirna is a biotechnology company developing next-generation infectious disease vaccines using its proprietary viRNA™ circular RNA platform.
Vaxxirna is focused on building a durable, scalable vaccine platform designed to address the limitations of first-generation linear mRNA technologies
and support programs across major infectious disease threats.

Vaxxirna strategy is platform-driven, with early clinical validation at the core of its investment thesis and continued innovation in the viRNA™ circular
RNA platform as its long-term engine.

Investment Highlights

Vaxxirna’s investment thesis is built around platform differentiation, disciplined execution, and a focused mandate in infectious disease and global health. Key elements include:

  • Proprietary viRNA™ circular RNA platform engineered for durability, tolerability, and real-world deployment
  • Focused pipeline across high-priority infectious disease and pandemic preparedness indications
  • Early clinical program designed to deliver platform proof-of-concept
  • Selective partnerships supporting AI-driven optimization, advanced delivery technologies, and GMP manufacturing
  • Experienced leadership team with deep backgrounds in RNA biology, vaccinology, infectious disease, pharma, and regulatory strategy

Vaxxirna is advancing multiple vaccine programs in parallel, powered by real-time data to accelerate decision-making and compress development timelines.

Development & Capital Strategy

Vaxxirna has initiated a Seed financing round to fund advancement of the viRNA™ platform across multiple infectious disease vaccine programs from
late-stage preclinical development through first-in-human clinical trials.

Initiation of first-in-human clinical trials
in infectious disease

Expansion of regulatory, clinical
operations, and business development
capabilities

Initiation and advancement of multiple
parallel clinical programs

Vaxxirna welcomes engagement from institutional investors and strategic partners aligned with long-term platform development and the shared
goal of bringing more effective, more accessible vaccines to the world.

View Our Pipeline

Vaccine Applications

The viRNA™ platform is being developed to support a broad range of infectious disease applications, including:

Platform Licensing

Revenue from licensing the viRNA™ vaccine technology to pharma and biotech partners for RNA-based vaccine development across infectious disease.

Co-development Partnerships

Joint programs with pharma and global health partners for specific viRNA™-based vaccine candidates across infectious disease indications.

Vaccine Out-licensing

Out-licensing of internally developed vaccine programs for clinical and commercial development by established partners.

Royalties on Commercial Sales

Long-term recurring income from partnered viRNA™ vaccine products once approved and commercialized.

Government & Institutional Contracts

Non-dilutive funding from government health agencies and global health organizations for priority infectious disease and pandemic preparedness programs.

Request Additional Materials

Vaxxirna provides its investor deck and related materials upon request. Please complete the form below to request access. A member of the
Vaxxirna team will follow up directly.